

The role of microRNAs in allergic airways disease and T cell biology

By
Maximilian Walter Plank
Dipl Biol

Thesis submitted in fulfillment of the requirements
to obtain the degree of Doctor of Philosophy
in Immunology and Microbiology

School of Biomedical Sciences and Pharmacy
University of Newcastle

May 2014

THESIS STATEMENT

This thesis contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying subject to the provisions of the Copyright Act 1968.

I hereby certify that the work embodied in this thesis contains a published paper/s/scholarly work of which I am a joint author. I have included as part of the thesis a written statement, endorsed by my supervisor, attesting to my contribution to the joint publication/s/scholarly work.

Maximilian Plank

May 2014

CONTRIBUTION TO CO-AUTHORED PAPERS

Chapter 1

Sections of the introduction (specifically relating to microRNAs, their functions in the immune system and in inflammatory disorders) have previously been published in an invited review (Paper 1) and contributed to a review on the emerging role of microRNAs in regulating immune and inflammatory responses in the lung (Paper 2).

Paper 1:

Plank M, Maltby S, Mattes J, Foster PS. Targeting translational control as a novel way to treat inflammatory disease: the emerging role of microRNAs. Clin Exp Allergy. 2013 Sep;43(9):981-99.

Paul Foster and Maximilian Plank initially conceptualised this manuscript. Maximilian Plank performed the literature search, generated figures and tables and wrote the initial complete draft. Paul Foster, Joerg Mattes and Steve Maltby contributed to the final version which was edited and submitted by Maximilian Plank.

Paper 2:

Foster PS, Plank M, Collison A, Tay HL, Kaiko GE, Li J, et al. The emerging role of microRNAs in regulating immune and inflammatory responses in the lung. Immunological reviews. 2013 May;253(1):198-215.

Paul Foster, Hock Tay, Adam Collison and Maximilian Plank initially conceptualised and Hock Tay, Adam Collison and Maximilian Plank contributed sections to the paper, which was collated and written by Paul Foster.

Laureate Professor Paul Foster

May 2014

ACKNOWLEDGEMENTS

I would like to give great thanks to my supervisor Laureate Professor Paul Foster for his wonderful mentoring and advice throughout my PhD studies. This has proved invaluable not only in the research presented herein but also in a broader scientific context moving towards a future career in medical research. I would further like to thank Laureate Professor Paul Foster for providing me with the resources to conduct a diverse array of research throughout my PhD, some of which did not make it into this thesis due to its focus on unrelated topics.

My co-supervisor Professor Phil Hansbro deserves a special mention for his guiding advice and help along the way. I would also like to thank my co-supervisor Associate Professor Joerg Mattes.

I would also like to extend my gratitudes to all the past and present colleagues that have helped me throughout my PhD. Special mention go to Dr. Steven Maltby, Dr. Nicole Hansbro, Dr. Gerard Kaiko, Dr. Hock Tay, Dr. Eric Lam, Jessica Stewart and Fiona Evers for all the help and support.

I would also like to thank Rebecca Wilson for her patience and support.

Finally, I would like to thank my parents and brothers for being awesome. You know it and words cannot describe my gratitude. Vielen Lieben Dank

TABLE OF CONTENTS

LIST OF FIGURES	IX
LIST OF TABLES	XI
LIST OF ABBREVIATIONS	XII
SYNOPSIS	15
CHAPTER I INTRODUCTION.....	16
I.1 SUMMARY	16
I.2 ASTHMA.....	17
I.3 TH CELLS	19
I.4 TH CELL SUBSETS	20
I.5 INFLAMMATORY CYTOKINES	23
I.5.1 Interferon- γ	23
I.5.2 Interleukin-5	24
I.5.3 Interleukin-13	25
I.5.4 Interleukin-17	25
I.6 MICRORNAS	25
I.7 MICRORNA BIOGENESIS	27
I.7.1 MicroRNA function	28
I.7.2 Targeting miRNA expression	30
I.7.3 Identification of miRNA targets in silico	31
I.7.4 Experimental identification of miRNA targets.....	32
I.8 THE ROLE OF MiRNAs IN THE IMMUNE SYSTEM.....	33
I.8.1 MiRNA function in immune cell development	33
I.8.2 MiRNA function in innate immunity	34
I.8.3 MiRNA function in adaptive immunity	36
I.9 MiRNA FUNCTION IN ALLERGIC AIRWAY DISEASES	38
I.10 MiRNAs IN CHRONIC RESPIRATORY DISORDERS	44
I.11 HYPOTHESIS AND AIMS OF THIS PHD	46
CHAPTER II MATERIALS AND METHODS.....	47
II.1 ANIMAL WORK	47
II.1.1 Mice.....	47
II.1.2 OVA-induced model of AAD.....	47
II.1.3 AHR measurement.....	48

II.2	COLLECTION AND ANALYSIS OF BAL FLUID	48
II.2.1	<i>Cytospin preparation of BAL fluid</i>	48
II.2.2	<i>BAL fluid differential cell counts</i>	48
II.3	EXTRACTION AND CULTURE OF CELLS	49
II.3.1	<i>Single cell preparation from whole lung</i>	49
II.3.2	<i>Extraction of lung cell subsets</i>	49
II.3.3	<i>Purification of naïve Th cells</i>	50
II.3.4	<i>CFSE labelling of CD4⁺ T cells</i>	50
II.3.5	<i>Generation of effector Th cell subsets</i>	50
II.3.6	<i>Collection and culture of PBLNs</i>	51
II.4	RNA EXTRACTION AND ANALYSIS.....	51
II.4.1	<i>Tissue preparation for RNA extraction</i>	51
II.4.2	<i>Isolation of total RNA</i>	51
II.4.3	<i>RNA quantification and quality analysis</i>	52
II.4.4	<i>Profiling of miRNA expression</i>	53
II.4.5	<i>Quantitative RT-PCR (qRT-PCR)</i>	54
II.4.5.1	Reverse transcription of mRNA	54
II.4.5.2	qRT-PCR for gene expression.....	54
II.4.5.3	Reverse transcription of miRNAs	56
II.4.5.4	qRT-PCR for miRNA expression.....	56
II.4.5.5	qRT-PCR data analysis.....	58
II.5	CYTOKINE ANALYSIS	58
II.6	LUNG HISTOLOGY	58
II.7	ANTAGOMIRS	58
II.8	FLOW CYTOMETRY	59
II.8.1	<i>Surface staining</i>	59
II.8.2	<i>Intracellular cytokine staining</i>	60
II.9	STATISTICAL ANALYSIS	61
CHAPTER III	RESULTS.....	62
III.1	ACUTE OVA-INDUCED MODEL OF AAD	62
III.2	DEX TREATMENT PREVENTS THE DEVELOPMENT OF AAD	65
III.3	MIRNA EXPRESSION PROFILING IN THE LUNG.....	70
III.4	EXPRESSION OF MIRNAS IN AIRWAY WALL AND PARENCHYMA	76
III.5	COMPUTATIONAL PREDICTION OF TARGET GENES.....	77
III.6	VALIDATION OF TARGET GENE EXPRESSION CHANGES	82
III.7	EXPRESSION OF MMU-MIR-155-5P AND -449A-5P ACROSS DIFFERENT TISSUES AND CELL TYPES	87
III.8	TARGETING OF MMU-MIR-155-5P AND -449A-5P <i>IN VIVO</i>	88
III.9	SPECIFICITY OF ANT-155 TREATMENT	89

III.10	EFFECT OF MMU-MIR-155-5P AND -449A-5P INHIBITION	91
III.11	EFFECT OF MMU-MIR-155-5P KNOCKDOWN ON PREDICTED TARGETS.....	94
III.12	EFFECTIVENESS OF MMU-MIR-155-5P KNOCKDOWN IN LUNG IMMUNE CELLS	95
III.13	CELLULAR DISTRIBUTION OF ANTAGOMIR DELIVERY IN THE LUNG	96
III.14	ANTAGOMIR UPTAKE <i>IN VITRO</i>	99
III.15	ANTAGOMIR-MEDIATED INHIBITION OF PROLIFERATION IN CD4 ⁺ T CELLS	101
III.16	GENERATION OF TH CELL SUBSETS.....	101
III.17	MIRNA PROFILING IN TH CELL SUBSETS	104
III.17.1	<i>Differential expression of miRNAs in naïve versus specific Th cell subsets.....</i>	<i>105</i>
III.17.2	<i>Differential expression of miRNAs in effector Th cell subsets</i>	<i>107</i>
III.17.3	<i>Confirmation of microarray expression data with qRT-PCR.....</i>	<i>109</i>
III.17.4	<i>MiRNA expression during Th cell differentiation.....</i>	<i>113</i>
III.18	EFFECT OF TARGETING MIRNAS DURING TH CELL DIFFERENTIATION	115
III.18.1	<i>Effect of antagomir treatment on Th2 cells</i>	<i>117</i>
III.18.2	<i>Effect of antagomir treatment on Th1 cells</i>	<i>119</i>
III.18.3	<i>Effect of antagomir treatment on Th17 cells</i>	<i>120</i>
III.18.4	<i>Effect of Ant-155 on cytokine expression in Th1 and Th2 cells</i>	<i>122</i>
CHAPTER IV	DISCUSSION	124
IV.1	INTRODUCTION	124
IV.2	MICROARRAY CHARACTERIZATION OF THE LUNG MIRNAOME IN AAD.....	124
IV.2.1	<i>Altered miRNAs associated with inflammatory diseases.....</i>	<i>125</i>
IV.2.2	<i>The effect of steroid treatment on miRNA expression in AAD</i>	<i>127</i>
IV.3	COMPUTATIONAL MIRNA TARGET PREDICTION IN AAD	128
IV.3.1	<i>Detection of predicted target genes in AAD.....</i>	<i>129</i>
IV.3.2	<i>Identification of target genes previously associated with asthma</i>	<i>129</i>
IV.3.3	<i>Identification of target genes with potentially novel roles in asthma</i>	<i>132</i>
IV.4	<i>IN VIVO</i> TARGETING OF MMU-MIR-155-5P AND -449A-5P IN AAD	133
IV.4.1	<i>Cellular distribution of intranasal antagomir delivery</i>	<i>134</i>
IV.4.2	<i>Specificity of Ant-155 treatment</i>	<i>134</i>
IV.4.3	<i>Mmu-miR-155-5p as a therapeutic target</i>	<i>135</i>
IV.4.4	<i>Ant-155 effect on putative target genes.....</i>	<i>136</i>
IV.4.5	<i>Mmu-miR-449a-5p as a therapeutic target</i>	<i>136</i>
IV.5	MIRNA CHARACTERIZATION IN TH CELL SUBSETS <i>IN VITRO</i>	138
IV.5.1	<i>Choice of in vitro Th cell culture system</i>	<i>139</i>
IV.5.2	<i>Generation of Th cell subsets in vitro</i>	<i>140</i>
IV.5.3	<i>Microarray characterization of the Th cell miRNAome.....</i>	<i>141</i>
IV.5.4	<i>Th cell miRNAs with a potential role in AAD</i>	<i>142</i>

IV.6	ANTAGOMIR UPTAKE AND FUNCTION	143
CHAPTER V	FUTURE DIRECTIONS	145
V.1	THE MIRNAOME IN AAD LUNG AND TH CELL SUBSETS.....	145
V.2	TARGETING ALTERED MIRNAS IN AAD <i>IN VIVO</i> WITH ANTAGOMIRS	145
V.3	MIRNA TARGET GENES IN AAD.....	146
V.4	THE ROLE OF MMU-MIR-155-5P IN AAD AND TH CELL FUNCTION.....	146
V.5	THE ROLE OF MMU-MIR-449A-5P IN AAD AND TH CELL FUNCTION.....	147
V.6	SUMMARY	148
SUPPLEMENTARY DATA		149
REFERENCES		167

LIST OF FIGURES

Figure 1: Differentiation and function of Th cell subsets.	21
Figure 2: MiRNA biogenesis	27
Figure 3: Different types of miRNA binding sites.....	29
Figure 4: Schematic overview of the OVA-induced model of AAD.	62
Figure 5: Induction of AHR.	63
Figure 6: Induction of airway inflammation with allergen challenge.	64
Figure 7: Eosinophil accumulation and induced mucus secretion in the lung.	65
Figure 8: Induction of AHR following DEX treatment.	66
Figure 9: Induction of airway inflammation with allergen challenge, after DEX treatment.	67
Figure 10: Recruitment of eosinophils and induction of mucus secretion in the lung, following DEX treatment.....	67
Figure 11: mRNA expression in whole lungs.	68
Figure 12: mRNA expression in airway wall and parenchyma.....	69
Figure 13: Production of proinflammatory Th2 cytokines.	69
Figure 14: Microarray detection of miRNAs in whole lung.	70
Figure 15: Dendrogram of differentially expressed miRNAs in whole lung.	73
Figure 16: Confirmation of differentially expressed miRNAs in whole lung.....	74
Figure 17: Correlation of differential miRNA expression.	75
Figure 18: Expression of mmu-miR-126-3p in whole lung.....	76
Figure 19: MiRNA expression in the airway wall and parenchyma.	77
Figure 20: Predicted target genes with multiple miRNA binding sites.....	80
Figure 21: Target gene expression in airway wall and parenchyma.	83
Figure 22: MiRNA expression in selected tissues and cell types.....	88
Figure 23: Effect of antagomir treatment on miRNA expression in the airway wall and parenchyma..	89
Figure 24: Mir-155 expression and specificity of antagomir treatment.....	90
Figure 25: Effect of antagomir treatment on the induction of AHR.....	92
Figure 26: Effect of antagomir treatment on the induction of airway inflammation.	93
Figure 27: Effect of antagomir treatment on the production of proinflammatory Th2 cytokines.....	93
Figure 28: Effect of antagomir treatment on mRNA expression in the airway wall and parenchyma..	94
Figure 29: Effect of Ant-155 treatment on target mRNA expression in whole lung.	95
Figure 30: Effect of antagomir treatment on mmu-miR-155-5p expression in different cell types in whole lung.	96
Figure 31: <i>In vivo</i> antagomir delivery efficacy into different lung cell types.....	97
Figure 32: Increases in CD11c ⁺ and CD4 ⁺ cells in the lung of OVA-sensitized/challenged mice.....	98

Figure 33: <i>In vitro</i> antagomir uptake into different lung cell types.	100
Figure 34: <i>In vitro</i> proliferation of CD4 ⁺ T cells treated with antagomir.	101
Figure 35: Schematic of Th cell differentiation.	102
Figure 36: Gene expression analysis in Th cell subsets.	103
Figure 37: Cytokine production by Th cell subsets.	104
Figure 38: Microarray detection of miRNAs in Th cells.	105
Figure 39: MiRNA expression in naïve versus effector Th cell subsets.	106
Figure 40: MiRNA expression in effector Th cell subsets.	107
Figure 41: Confirmation of differentially expressed miRNAs in Th cells by qRT-PCR.	110
Figure 42: Comparison of miRNA expression patterns between microarray and qRT-PCR.	113
Figure 43: Transcription factor expression during Th cell differentiation.	114
Figure 44: MiRNA expression during Th cell differentiation.	115
Figure 45: Antagomir targeting knockdown efficiency during Th2 differentiation.	116
Figure 46: Predicted targeting of Gata3 by mmu-miR-449a-5p.	117
Figure 47: Effect of antagomirs on Th2 cell differentiation.	118
Figure 48: Effect of antagomirs on Th1 cell differentiation.	120
Figure 49: Effect of antagomirs on Th17 cell differentiation.	121
Figure 50: Effect of Ant-155 on cytokine expression in Th1 and Th2 cells.	123
Figure 51: Multiple sequence alignment of mature mir-34/449 family miRNAs.	137
Figure 52: Ant-449 targeting of mmu-miR-449a-5p and related family members.	138
Supplementary Figure 53: Peak of inflammation and AHR at day 16.	149
Supplementary Figure 54: MiRNA detection in Th cells.	159

LIST OF TABLES

Table 1: Overview of available programs for the prediction of miRNA-gene interactions.	32
Table 2: List of miRNAs associated with inflammatory lung diseases.	39
Table 3: Selected miRNAs associated with inflammatory diseases, their verified targets in inflammatory disease and other potential disease-relevant targets.	40
Table 4: Antibodies used for separation.	50
Table 5: Primer sequences used for qRT-PCR analysis.	55
Table 6: Taqman miRNA assays used in this study.	57
Table 7: Antagomirs used in this study.	59
Table 8: Antibodies used for FACS analysis and cell separation.	60
Table 9: Differentially expressed miRNAs in whole lung.	71
Table 10: Target gene prediction for 29 differentially expressed miRNAs.	79
Table 11: Predicted target genes with multiple target sites.	81
Table 12: MiRNA binding sites in selected target genes.	84
Table 13: Differentially expressed miRNAs in effector Th cell subsets.	108
Supplementary table 14: Complete list of detected miRNAs in whole lung.	150
Supplementary table 15: List of differentially expressed miRNAs.	156
Supplementary table 16: Putative target gene information.	157
Supplementary table 17: Complete list of miRNAs detected in Th cells.	160
Supplementary table 18: Differentially expressed miRNAs in naïve and effector Th cells.	164

LIST OF ABBREVIATIONS

-/-	knockout mouse
AAD	allergic airways disease
AD	allergic dermatitis
AEC	airway epithelial cell
AHR	airways hyperreactivity
Ant	antagomir
APC	allophycocyanin, antigen presenting cell
bp	basepair
BSA	bovine serum albumin
c-Myb	transcriptional activator Myb
CCL	chemokine ligand
CFSE	carboxyfluorescein diacetate succinimidyl ester
Chr	chromosome
Chol	cholesterol
CIP	calf intestine alkaline phosphatase
COPD	chronic obstructive pulmonary disease
COX2	cyclooxygenase 2
CxCL	chemokine (c-X-c motif) ligand
Da	dalton
DC	dendritic cell
DEX	dexamethasone
DGCR8	DiGeorge syndrome critical region gene 8
DMEM	Dulbecco's modified eagle medium
DNA	deoxyribonucleic acid
dsDNA	double-stranded DNA
dNTP	deoxyribonucleic triphosphate
EAE	experimental autoimmune encephalomyelitis
EDTA	ethylenediaminetetraacetic acid
FCS	fetal calf serum
FITC	fluorescein
FoxO1	forkhead box O1
FoxP3	forkhead box P3
Gata3	GATA binding protein 3
GSK3B	glycogen synthase kinase-3 β
HBSS	Hanks buffered saline solution
HDM	house dust mite
HPF	high power field
ICS	inhaled corticosteroids
IFN	interferon
Ig	immunoglobulin

IL	interleukin
i.n.	intranasal
IRAK1	IL-1 receptor associated kinase
iTreg	induced regulatory T cell
JNK	c-Jun NH(2)-terminal kinase
LCs	Langerhans cells
Let-7	lethal 7
LPS	lipopolysaccharide
miRNA	microRNA (micro ribonucleic acid)
MyD88	myeloid differentiation primary response gene (88)
NF- κ B	nuclear factor kappa-light-chain-enhancer of activated B cells
NK	natural killer
OBF.1/BOB.1	POU domain class 2 associating factor 1
OVA	ovalbumin
OVA/OVA	OVA sensitised/OVA challenged mice
OVA/OVA DEX	OVA/OVA mice treated with dexamethasone
PAMP	pathogen-associated molecular pattern
PDCD4	programmed cell death protein 4
PBLN	peribronchial lymph node cells
PBMC	peripheral blood mononuclear cells
PBS	phosphate buffered saline
PBS/PBS	PBS sensitised/PBS challenged mice
PBS/OVA	PBS sensitised/OVA challenged mice
PCR	polymerase chain reaction
PE	r-phycoerythrin
PE-Cy7	r-phycoerythrin-Cy7 conjugate
PerCP-Cy5.5	peridinin-chlorophyll-protein complex: Cy5.5 conjugate
PGE2	prostaglandin E2
PMNs	polymorphonuclear neutrophils
Pri-miRNA	primary microRNA transcript
PTEN	phosphatase and tensin homologue
qRT-PCR	quantitative real-time PCR
RA	rheumatoid arthritis
RANTES	regulated and normal T cell expressed and secreted
RBC	red blood cell
RISC	RNA-inducing signalling complex
RNA	ribonucleic acid
ROR γ t	retinoid orphan receptor γ t
RPM	rounds per minute
Scramble	Scrambled control antagomir
SHIP1	SH2 domain-containing inositol phosphatase 1
siRNA	short interfering ribonucleic acid
SOCS1	suppressor of cytokine signalling 1
SPF	specific pathogen-free

ssDNA	single-stranded DNA
STAT	signal transducer and activator of transcription
TAB2 protein 2	mitogen-activated protein kinase kinase kinase 7 binding
Tbet	T-box transcription factor expressed in T cells
TCR	T cell receptor
TGF- β	transforming growth factor beta
Th	T helper
TLR	toll like receptor
TNF	tumour necrosis factor
TOM1	target of Myb1
TRAF6	TNF receptor-associated factor 6
TRAIL	tumour necrosis factor – related apoptosis - inducing ligand
TRBP	TAR RNA-binding protein
Treg	regulatory T cell
UTR	untranslated region

SYNOPSIS

MicroRNAs (miRNAs) are post-transcriptional regulators of gene expression and their cellular expression is differentially regulated at various developmental and functional stages. The objective of my PhD research was to assess 1) whether miRNAs are differentially regulated in an ovalbumin-induced model of allergic airways disease, 2) whether corticosteroid (dexamethasone) treatment alters miRNA expression, 3) whether miRNAs play a functional role in disease development, 4) whether miRNAs are differentially regulated in Th cell differentiation and 5) whether miRNAs play a functional role in Th cell differentiation and function. To address these questions, we performed miRNA profiling on the lungs of allergic mice and compared these profiles to lung profiles from dexamethasone-treated mice and non-allergic controls, using miRNA microarray analysis and real-time PCR. We generated distinct miRNA signatures and identified 29 miRNAs that showed significantly altered expression in allergic lungs. Analysis of predicted miRNA targets revealed novel target genes with altered mRNA expression and demonstrated synergistic miRNA regulation within allergic lungs. Using antagomirs, we inhibited the function of two specific miRNAs (mmu-miR-155-5p and mmu-miR-449a-5p) in the airway wall and investigated the effect on hallmark features of allergic airways disease. While antagomir administration successfully reduced expression of targeted miRNAs, it failed to induce alterations to disease phenotype, suggesting multiple miRNAs regulate changes associated with allergic disease. We further show that antagomir delivery to the lung achieves only variable efficacy across different cell types. While antagomir delivery efficiently reduced specific miRNA expression in myeloid cells, lymphocytes are only partially targeted, suggesting that therapeutic targeting of miRNA function in lymphocytes may require a different approach. We further performed miRNA profiling in naïve and effector Th cells *in vitro* and identified a global up-regulation of miRNA expression in activated Th cells. Using antagomirs, we inhibited the function of several miRNAs and again found that antagomir delivery to Th cells proves inadequate for suppression of target miRNA expression.